Diisocyanates, such as toluene 2, 4-diisocyanate (TDI) are the principal cause of occupational asthma induced by low molecular weight chemicals. Recently, the study of immune regulation by microRNAs has revealed the importance of these regulatory molecules in allergic disease. Our laboratory has shown that miRNA 210 (miR-210) expression increases in the draining lymph nodes (DLN) following dermal exposure to TDI in a murine model, however, the role of miR-210 in allergic disease is unknown. These studies were conducted to elucidate the functional role of miR-210 during sensitization to TDI. Female BALB/c mice were dermally exposed to TDI (4%) or vehicle. RNA was isolated from specific cellular subsets (T-cells and B-cells) at four days post exposure and analyzed for miR-210 expression using real-time quantitative polymerase chain reaction analysis. A statistically significant increase in miR-210 expression occurred in the DLN CD4+ cell population of TDI-exposed mice. Confirmed (foxp3) and predicted (runx1t1, runx3, smad4, and stat6) miR-210 transcription factor targets were identified using computational algorithms. Augmentations in foxp3 protein expression and decreases in runx1 and foxp3 mRNA occurred concurrently with expression of miR-210 following dermal TDI exposure. Understanding the immunologic mechanisms of allergic disease is critical for the development of preventative and therapeutic strategies and these studies suggest a functional role for miR-210 in the regulatory T cell pathway and ultimately in the pathogenesis of TDI sensitization.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.